Zydus' sales up by 21% on formulations, US growth
This article was originally published in Scrip
Executive Summary
Zydus Cadila has reported a 21% increase in net sales to Rs11.06 billion ($249.4 million) for the second quarter ended 30 September compared with the same quarter in the previous year, backed by strong growth in its formulations and US businesses. Net profit rose by 30% to Rs1.70 billion.
You may also be interested in...
Sun’s Ilumya To Claw Into Japanese Psoriasis Market
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
'Covidization' Of Resources Brings Huge Disruption For TB Patients, Researchers
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
Ex-Cipla Executive To Helm JB Chemicals
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.
Need a specific report? 1000+ reports available
Buy Reports